JSKN003 Shows 100% ORR in First-Line Gastric Cancer and 23.5-Month Median OS in Ovarian Cancer at 2026 ESMO
Start here
Alphamab presented two posters on its HER2-targeting antibody-drug conjugate JSKN003 at the 2026 ESMO meeting. In previously untreated HER2-positive gastric cancer, the JSKN003-003 trial (NCT06998771) enrolled 25 patients across three first-line cohorts; the cohort combining JSKN003 with KN026 achieved an objective response rate of 100%, while cohorts A and C showed 71.4% and 50.0% respectively. At a median follow-up of 5.2 months, duration of response, progression-free survival and overall survival were not yet mature, and grade 3 or higher treatment-related adverse events in cohort B occurred in 28.6% of patients. In platinum-resistant ovarian cancer, updated monotherapy data showed a median overall survival of 23.5 months. Longer-term survival and tolerability data remain outstanding.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comAlphamab's JSKN003 at 2026 ESMO: 100% ORR in First-Line Gastric Cancer Combination With KN026, Median OS 23.5 Months in Platinum-Resistant Ovarian Cancer
Alphamab presented two JSKN003 posters at 2026 ESMO. In first-line HER2-positive gastric cancer, the combination cohort with KN026 achieved an ORR of 100%, and in platinum-resistant ovarian cancer, updated monotherapy data showed a median OS of 23.5 months. The JSKN003-003 trial (NCT06998771) first-line cohort enrolled 25 patients, with ORRs of 71.4%, 100% and 50.0% in cohorts A, B and C; at a median follow-up of 5.2 months, DoR, PFS and OS were not yet mature, and grade 3 or higher TRAEs in cohort B were 28.6%.
Heat trend for this story
Heat now 8·Peak in the comparable set 10 (Oct 28 10:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.